Kyverna Therapeutics Revenue and Competitors

Location

#1429

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Kyverna Therapeutics's estimated annual revenue is currently $18.8M per year.(i)
  • Kyverna Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Kyverna Therapeutics has 121 Employees.(i)
  • Kyverna Therapeutics grew their employee count by 64% last year.

Kyverna Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head Human ResourcesReveal Email/Phone
3
V.P. Corporate DevelopmentReveal Email/Phone
4
VP Human ResourcesReveal Email/Phone
5
VP, Program LeadReveal Email/Phone
6
VP, Regulatory Affairs and QualityReveal Email/Phone
7
SVP, Head ResearchReveal Email/Phone
8
Associate Director Quality ControlReveal Email/Phone
9
Associate Director, Quality SystemsReveal Email/Phone
10
Associate Director Project ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Kyverna Therapeutics?

Kyverna is a cell therapy company engineering and developing a new class of curative living medicines for inflammatory and autoimmune diseases. Using its SmarTcellâ„¢ approach which includes synReg-T cell and synNotch CAR-T technology platforms, Kyverna reprograms T cells to target and selectively suppress or eliminate autoreactive immune cells. The company's goal is to develop therapies that are selective, potent and durable to tame autoimmunity. synNotch is a trademark of Gilead/Kite.

keywords:N/A

N/A

Total Funding

121

Number of Employees

$18.8M

Revenue (est)

64%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kyverna Therapeutics News

2022-02-22 - Kyverna Therapeutics Closes $85 Million Series B Financing led by ...

The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress or eliminate the...

2022-02-22 - Gilead backed Kyverna Therapeutics closes $85m Series B ...

Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for autoimmune diseases, has closed an oversubscribed $85m...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.1M124-18%N/A
#2
N/A1251%N/A
#3
$18.1M125-5%N/A
#4
$18.1M125-5%N/A
#5
$34M1265%N/A